Latest Vioxx verdict is win number five for Merck

Share this article:
Merck has been cleared of responsibility in the heart attack of a former Vioxx patient in the 10th case to go to trial over the withdrawn painkiller. The latest verdict brings the trial tally to five wins and four losses for Merck. A new trial was granted for the remaining verdict in New Jersey last month, following the emergence of new data in that case. In the latest case, a federal jury in New Orleans ruled Merck had adequately warned of Vioxx’s heart risks and stated that Vioxx wasn’t the cause of the heart attack of Robert Smith, 56, of Florence, KY. Merck withdrew Vioxx from the market after a study linked the drug to heart risks two years ago this week.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.